ReviewClinical rheumatology2022

Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation.

Takahiro Itamiya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.